Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

PHASE3TerminatedINTERVENTIONAL
Enrollment

327

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

April 30, 2016

Conditions
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Interventions
DRUG

Pacritinib

DRUG

Best Available Therapy

Trial Locations (81)

29601

CTI Investigational Site 10003, Greenville

68198

CTI Investigational Site 10004, Omaha

85259

CTI Investigational Site 10002, Scottsdale

07962

CTI Investigational Site 10001, Morristown

Unknown

CTI Investigational Site 61006, Box Hill

CTI Investigational Site 61001, Coffs Harbour

CTI Investigational Site 61005, Geelong

CTI Investigational Site 61003, Gosford

CTI Investigational Site 61004, Hobart

CTI Investigational Site 61002, Milton

CTI Investigational Site 32002, Antwerp

CTI Investigational Site 32003, Antwerp

CTI Investigational Site 32001, Bruges

CTI Investigational Site 32005, Brussels

CTI Investigational Site 32004, La Louvière

CTI Investigational Site 42003, Brno

CTI Investigational Site 42001, Olomouc

CTI Investigational Site 42002, Pilsen

CTI Investigational Site 42004, Prague

CTI Investigational Site 33005, Amiens

CTI Investigational Site 33006, Caen

CTI Investigational Site 33011, Grenoble

CTI Investigational Site 33012, Lens

CTI Investigational Site 33007, Lille

CTI Investigational Site 33001, Nîmes

CTI Investigational Site 33004, Paris

CTI Investigational Site 33008, Paris

CTI Investigational Site 33009, Pessac

CTI Investigational Site 33010, Pierre-Bénite

CTI Investigational Site 33003, Strasbourg

CTI Investigational Site 33002, Toulouse

CTI Investigational Site 49006, Berlin

CTI Investigational Site 49007, Berlin

CTI Investigational Site 49001, Cologne

CTI Investigational Site 49003, Dresden

CTI Investigational Site 49008, Essen

CTI Investigational Site 49002, Freiburg im Breisgau

CTI Investigational Site 49005, Mainz

CTI Investigational Site 49004, München

CTI Investigational Site 49009, Münster

CTI Investigational Site 36002, Budapest

CTI Investigational Site 36005, Debrecen

CTI Investigational Site 36006, Gyula

CTI Investigational Site 36003, Kaposvár

CTI Investigational Site 36004, Kecskemét

CTI Investigational Site 36001, Szeged

CTI Investigational Site 36008, Szolnok

CTI Investigational Site 36007, Szombathely

CTI Investigational Site 39003, Bologna

CTI Investigational Site 39001, Florence

CTI Investigational Site 39005, Milan

CTI Investigational Site 39004, Monza

CTI Investigational Site 39002, Padua

CTI Investigational Site 39008, Reggio Emilia

CTI Investigational Site 39006, Rimini

CTI Investigational Site 31001, Amsterdam

CTI Investigational Site 31002, Maastricht

CTI Investigational Site 31003, Rotterdam

CTI Investigational Site 31004, Utrecht

CTI Investigational Site 64001, Christchurch

CTI Investigational Site 64004, Dunedin

CTI Investigational Site 64002, Hamilton

CTI Investigational Site 64003, Takapuna

CTI Investigational Site 70011, Izhevsk

CTI Investigational Site 70008, Moscow

CTI Investigational Site 70009, Moscow

CTI Investigational Site 70002, Petrozavodsk

CTI Investigational Site 70001, Saint Petersburg

CTI Investigational Site 70004, Saint Petersburg

CTI Investigational Site 70010, Saint Petersburg

CTI Investigational Site 70005, Samara

CTI Investigational Site 70006, Sochi

CTI Investigational Site 70007, Volgograd

CTI Investigational Site 44004, Birmingham

CTI Investigational Site 44008, Bournemouth

CTI Investigational Site 44002, Cambridge

CTI Investigational Site 44003, Cardiff

CTI Investigational Site 44001, London

CTI Investigational Site 44007, London

CTI Investigational Site 44006, Manchester

CTI Investigational Site 44005, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CTI BioPharma

INDUSTRY